BriaCell Therapeutics Corp. engages in developing immunotherapies for the treatment of cancer.Lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors. Company also has a cooperative research and development agreement with the National Cancer Institute.